"Endo's statewide record of misconduct is plain for all to see, and the years-long record of their actions remains the same, regardless of the judge or venue," said Gerard Stranch of Branstetter, Stranch & Jennings, a lawyer for the plaintiffs. In a unanimous ruling Wednesday, a three-judge panel of the Court of Appeals of Tennessee at Knoxville also threw out the unusual sanction, in which Judge Jonathan Young of the Circuit Court for Cumberland County found Endo liable by default.
#WORDS WITH ENDO UPDATE#
Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.(Reuters) - A Tennessee judge who harshly sanctioned drugmaker Endo International Plc in a lawsuit by cities and counties over its alleged role in the opioid epidemic was biased against the company and should have recused himself, an appeals court ruled, ordering the case reassigned.
Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the impact of the ongoing COVID-19 pandemic on our business, revenues, results of operations and financial condition, the net sales, profitability, and growth of Esperion's commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes of legal proceedings, and the risks detailed in Esperion's filings with the Securities and Exchange Commission. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements.
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. The CLEAR Program includes 5 label-enabling Phase III studies as well as other key Phase IV studies with the potential to reach more than 70 million people with or at risk for CVD based on elevated LDL-C. More than 60,000 people will have participated in the program by the time of its completion. The CLEAR Program seeks to generate important clinical evidence on the safety and efficacy of bempedoic acid, a first in a class ATP citrate lyase inhibitor contained in NEXLETOL and NEXLIZET and its potential role in addressing additional critical unmet medical needs. For more information, visit and and follow us on Twitter at /EsperionInc.ĬLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet. Because when it comes to high cholesterol, getting to goal is not optional. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible we provide the next steps to help get patients there. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
0 kommentar(er)
